scholarly journals Alterations of Gene Expression and Glutamate Clearance in Astrocytes Derived from an MeCP2-Null Mouse Model of Rett Syndrome

PLoS ONE ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. e35354 ◽  
Author(s):  
Yasunori Okabe ◽  
Tomoyuki Takahashi ◽  
Chiaki Mitsumasu ◽  
Ken-ichiro Kosai ◽  
Eiichiro Tanaka ◽  
...  
2016 ◽  
Vol 3 (1) ◽  
Author(s):  
Pamela Millar-Büchner ◽  
Amber R. Philp ◽  
Noemí Gutierrez ◽  
Sandra Villanueva ◽  
Bredford Kerr ◽  
...  
Keyword(s):  

2018 ◽  
Vol 115 (23) ◽  
pp. E5363-E5372 ◽  
Author(s):  
Sivan Osenberg ◽  
Ariel Karten ◽  
Jialin Sun ◽  
Jin Li ◽  
Shaun Charkowick ◽  
...  

Rett syndrome (RTT) is a severe neurodevelopmental disorder that affects about 1 in 10,000 female live births. The underlying cause of RTT is mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2); however, the molecular mechanism by which these mutations mediate the RTT neuropathology remains enigmatic. Specifically, although MeCP2 is known to act as a transcriptional repressor, analyses of the RTT brain at steady-state conditions detected numerous differentially expressed genes, while the changes in transcript levels were mostly subtle. Here we reveal an aberrant global pattern of gene expression, characterized predominantly by higher levels of expression of activity-dependent genes, and anomalous alternative splicing events, specifically in response to neuronal activity in a mouse model for RTT. Notably, the specific splicing modalities of intron retention and exon skipping displayed a significant bias toward increased retained introns and skipped exons, respectively, in the RTT brain compared with the WT brain. Furthermore, these aberrations occur in conjunction with higher seizure susceptibility in response to neuronal activity in RTT mice. Our findings advance the concept that normal MeCP2 functioning is required for fine-tuning the robust and immediate changes in gene transcription and for proper regulation of alternative splicing induced in response to neuronal stimulation.


PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e100215 ◽  
Author(s):  
Weixiang Guo ◽  
Keita Tsujimura ◽  
Maky Otsuka I. ◽  
Koichiro Irie ◽  
Katsuhide Igarashi ◽  
...  

2017 ◽  
Vol 5 (2) ◽  
pp. e13110 ◽  
Author(s):  
Weiwei Zhong ◽  
Christopher M. Johnson ◽  
Ningren Cui ◽  
Max F. Oginsky ◽  
Yang Wu ◽  
...  

eLife ◽  
2016 ◽  
Vol 5 ◽  
Author(s):  
Dorothy P Schafer ◽  
Christopher T Heller ◽  
Georgia Gunner ◽  
Molly Heller ◽  
Christopher Gordon ◽  
...  

Microglia, the resident CNS macrophages, have been implicated in the pathogenesis of Rett Syndrome (RTT), an X-linked neurodevelopmental disorder<xref ref-type="bibr" rid="bib19"/><xref ref-type="bibr" rid="bib15"/><xref ref-type="bibr" rid="bib37"/><xref ref-type="bibr" rid="bib47"/>. However, the mechanism by which microglia contribute to the disorder is unclear and recent data suggest that microglia do not play a causative role<xref ref-type="bibr" rid="bib67"/>. Here, we use the retinogeniculate system to determine if and how microglia contribute to pathogenesis in a RTT mouse model, the Mecp2 null mouse (Mecp2tm1.1Bird/y). We demonstrate that microglia contribute to pathogenesis by excessively engulfing, thereby eliminating, presynaptic inputs at end stages of disease (≥P56 Mecp2 null mice) concomitant with synapse loss. Furthermore, loss or gain of Mecp2 expression specifically in microglia (Cx3cr1CreER;Mecp2fl/yor Cx3cr1CreER; Mecp2LSL/y) had little effect on excessive engulfment, synapse loss, or phenotypic abnormalities. Taken together, our data suggest that microglia contribute to end stages of disease by dismantling neural circuits rendered vulnerable by loss of Mecp2 in other CNS cell types.


2017 ◽  
Vol 381 ◽  
pp. 923
Author(s):  
H. Kida ◽  
T. Takahashi ◽  
Y. Nakamura ◽  
T. Kinoshita ◽  
S. Okayama ◽  
...  

2020 ◽  
Vol 29 (15) ◽  
pp. 2461-2470
Author(s):  
Jonathan K Merritt ◽  
Bridget E Collins ◽  
Kirsty R Erickson ◽  
Hongwei Dong ◽  
Jeffrey L Neul

Abstract Rett syndrome (RTT) is a neurodevelopmental disorder primarily caused by mutations in Methyl-CpG-binding Protein 2 (MECP2). More than 35% of affected individuals have nonsense mutations in MECP2. For these individuals, nonsense suppression has been suggested as a possible therapeutic approach. To assess the viability of this strategy, we created and characterized a mouse model with the common p.R294X mutation introduced into the endogenous Mecp2 locus (Mecp2R294X). Mecp2R294X mice exhibit phenotypic abnormalities similar to those seen in complete null mouse models; however, these occur at a later time point consistent with the reduced phenotypic severity seen in affected individuals containing this specific mutation. The delayed onset of severe phenotypes is likely due to the presence of truncated MeCP2 in Mecp2R294X mice. Supplying the MECP2 transgene in Mecp2R294X mice rescued phenotypic abnormalities including early death and demonstrated that the presence of truncated MeCP2 in these mice does not interfere with wild-type MeCP2. In vitro treatment of a cell line derived from Mecp2R294X mice with the nonsense suppression agent G418 resulted in full-length MeCP2 protein production, demonstrating feasibility of this therapeutic approach. Intraperitoneal administration of G418 in Mecp2R294X mice was sufficient to elicit full-length MeCP2 protein expression in peripheral tissues. Finally, intracranial ventricular injection of G418 in Mecp2R294X mice induced expression of full-length MeCP2 protein in the mouse brain. These experiments demonstrate that translational read-through drugs are able to suppress the Mecp2 p.R294X mutation in vivo and provide a proof of concept for future preclinical studies of nonsense suppression agents in RTT.


2006 ◽  
Vol 21 (1) ◽  
pp. 217-227 ◽  
Author(s):  
Yukiko Asaka ◽  
Denis G.M. Jugloff ◽  
Liang Zhang ◽  
James H. Eubanks ◽  
Reiko Maki Fitzsimonds

Sign in / Sign up

Export Citation Format

Share Document